LEXINGTON, Mass. ( TheStreet) -- Antigenics ( AGEN) could seek to raise up to $100 million by selling a mix of stock and debt, according to a new shelf registration statement filed with the Securities and Exchange Commission Friday. Antigenics has been relatively quiet since last November when European regulators turned down the company's application seeking approval of its kidney cancer vaccine Oncophage. Oncophage was approved in Russia in April 2008, but Antigenics has not been able to sell the drug there because it hasn't yet negotiated reimbursement with the Russian government. Antigenics sought Oncophage's approval in Europe on the basis of a failed phase III study. For that reason, the company can't file for approval in the U.S. In a recent interview, Antigenics' CEO Garo Armen said drug regulators in the U.S. and Europe were "too rigid" to approve Oncophage. As of Sept. 30, 2009, Antigenics had cash totaling $34 million, which the company said was sufficient to last into 2011. Antigenics has not yet reported fourth-quarter results, but the company was expected to burn $25 million in cash in 2009. The new $100 million shelf filed by Antigenics has not yet been declared effective by the SEC. The company didn't specify how much stock and/or debt it intends to sell, or when. Antigenics shares were down 8% to 74 cents in recent Monday trading.